Crescent Biopharma, Inc. (CBIO) — Net Asset Quality Index
Crescent Biopharma, Inc. (CBIO) has a Net Asset Quality Index of 89.3% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $182.76 Million minus total liabilities of $19.50 Million yields net assets of $163.25 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read Crescent Biopharma, Inc. total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Crescent Biopharma, Inc. Net Asset Quality Index Over Time (2011–2025)
This chart shows how Crescent Biopharma, Inc.'s Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 89.3%, representing net assets of $163.25 Million against total assets of $182.76 Million USD. For live market cap and overall valuation, see Crescent Biopharma, Inc. (CBIO) market capitalisation.
Annual Net Asset Quality Index for Crescent Biopharma, Inc. (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Crescent Biopharma, Inc. from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See CBIO total equity for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.5% | $203.01 Million | $240.29 Million | $37.28 Million | ▲ +127.9 pp |
| 2024 | -43.5% | $-15.48 Million | $35.62 Million | $51.10 Million | ▼ -128.2 pp |
| 2023 | 84.8% | $38.41 Million | $45.32 Million | $6.90 Million | ▲ +1.9 pp |
| 2022 | 82.9% | $42.93 Million | $51.81 Million | $8.88 Million | ▼ -3.6 pp |
| 2021 | 86.5% | $81.60 Million | $94.35 Million | $12.74 Million | ▼ -3.3 pp |
| 2020 | 89.8% | $128.22 Million | $142.83 Million | $14.61 Million | ▼ -2.0 pp |
| 2019 | 91.8% | $154.20 Million | $167.97 Million | $13.77 Million | ▼ -3.8 pp |
| 2018 | 95.6% | $205.46 Million | $214.84 Million | $9.38 Million | ▲ +2.5 pp |
| 2017 | 93.1% | $119.70 Million | $128.58 Million | $8.88 Million | ▲ +9.8 pp |
| 2016 | 83.3% | $35.30 Million | $42.39 Million | $7.09 Million | ▼ -0.2 pp |
| 2015 | 83.5% | $40.47 Million | $48.46 Million | $7.99 Million | ▼ -5.2 pp |
| 2014 | 88.7% | $50.80 Million | $57.26 Million | $6.46 Million | ▲ +33.7 pp |
| 2013 | 55.0% | $2.91 Million | $5.28 Million | $2.38 Million | ▼ -13.0 pp |
| 2012 | 68.0% | $12.53 Million | $18.42 Million | $5.89 Million | ▲ +38.8 pp |
| 2011 | 29.3% | $8.46 Million | $28.91 Million | $20.45 Million | — |